AMEX · AGE
Healthcare · Biotechnology
$11.10
Down-$1.50 (-11.90%)
Updated Aug 14, 2026, 11:06 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
AGE does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning AGE.
AGE research
Company profile and research snapshot.
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Mar 22, 2024
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2023 and recent highlights.
Benzinga · Nov 24, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By 5 Years Puma Biotechnology, Inc. (NASDAQ: PBYI) announced the U.S. Patent and Trademark Office issued a patent term extension certificate, extending the patent regarding the composition of matter claims for its breast cancer drug Nerlynx by five years. The patent will now expire on Dec. 29, 2030. The stock was up 5.66% to $3.36 in premarket trading. Click here to access Benzinga's FDA Calendar Takeda Receives FDA Approval For Drug to Treat Post-Transplant Cytomegalovirus Infection Takeda Pharmaceutical Company Limited (NYSE: TAK) announced the U.S. Food and Drug Administration has approved Livtencity for the treatment of adults and pediatric patients with post-transplant cytomegalovirus infection/disease that is refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet. Livtencity is Takeda's second new molecular entity to receive FDA approval in fiscal year 2021. In premarket trading, the stock was gaining 0.87% to $13.91. BeiGene's Brukinsa Receives European Regulatory Nod For A Type of Rare ...
Benzinga · Jul 26, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Lockheed Martin Corporation (NYSE: LMT) to report quarterly earnings at $6.53 per share on revenue of $16.93 billion before the opening bell. Lockheed Martin shares rose 0.1% to $380.80 in after-hours trading. Analysts are expecting Tesla Inc (NASDAQ: TSLA) to have earned $0.96 per share on revenue of $11.21 billion for ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AGE.
No results
No recent SID articles mention AGE.
